Of these, control of translation appears to exert the most important effect in FLC and is targetable with the clinical eukaryotic Initiation Factor 4A (eIF4A) inhibitor zotatifin, leading to reduced c-MYC protein expression and tumor cell viability. This evidence concerns the gene MYC and neoplasm.